Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase-4 inhibitors: Real world evidence from the Nordic EMPRISE study.

Thomas NyströmEmilie Toresson GripJoel GunnarssonPaula CasajustKristina KarlsdotterJosefin SkogsbergAnastasia Ustyugovanull null

Published in: Diabetes, obesity & metabolism (2022)

Empagliflozin treatment compared to DPP-4i reduced cardiorenal events and overall mortality, which may explain lower HCRU among empagliflozin users in Sweden.

Keyphrases

healthcare
cardiovascular events
risk factors
replacement therapy
health insurance